Breast Cancer Clinical Trials in Atlanta, Georgia

23 studies are recruiting for breast cancer in Atlanta, Georgia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

    The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Winship Cancer Institute, Atlanta, Georgia
    Locations
    567 in total
    Run by
    Stemline Therapeutics, Inc.

    See if you can join NCT06492616 on ClinicalTrials.gov

  2. A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

    The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with e…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Emory University (Data Collection Only), Atlanta, Georgia
    Locations
    10 in total
    Run by
    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05570253 on ClinicalTrials.gov

  3. A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors

    The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) an…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Winship Cancer Center Emory University, Atlanta, Georgia
    Locations
    50 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT05307705 on ClinicalTrials.gov

  4. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

    The purpose of this study is to assess the safety of GDC-4198 alone and in combination with giredestrant and also the efficacy of GDC-4198 + giredestrant versus abemaciclib + giredestrant in participants with locally advanced or metastatic ER+, HER2- breast cancer. The study consists of 2 phases: P…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Winship Cancer Institute of Emory University, Atlanta, Georgia
    Locations
    64 in total
    Run by
    Genentech, Inc.

    See if you can join NCT07100106 on ClinicalTrials.gov

  5. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Atlanta Cancer Care - Northside Hospital, Atlanta, Georgia
    Locations
    231 in total
    Run by
    Relay Therapeutics, Inc.

    See if you can join NCT06982521 on ClinicalTrials.gov

  6. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

    Stage
    Phase 3
    Ages
    18 to 60
    Site
    Grady Health System, Atlanta, Georgia
    Locations
    1261 in total
    Run by
    NRG Oncology

    See if you can join NCT05879926 on ClinicalTrials.gov

  7. Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

    This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor [Retifanlimab], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Winship Cancer Institute of Emory University, Atlanta, Georgia
    Locations
    79 in total
    Run by
    BriaCell Therapeutics Corporation

    See if you can join NCT06072612 on ClinicalTrials.gov

  8. A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

    This is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2) -negative, PIK…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Emory University Hospital, Atlanta, Georgia
    Locations
    210 in total
    Run by
    Hoffmann-La Roche

    See if you can join NCT05646862 on ClinicalTrials.gov

  9. Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

    Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conduc…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Emory University - Winship Cancer Institute, Atlanta, Georgia
    Locations
    10 in total
    Run by
    Nammi Therapeutics Inc

    See if you can join NCT06582017 on ClinicalTrials.gov

  10. A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

    This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inop…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Atlanta, Georgia
    Locations
    320 in total
    Run by
    AstraZeneca

    See if you can join NCT06103864 on ClinicalTrials.gov

  11. FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

    This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of RGT-419B administered orally as monotherapy OR in combination with Hormonal Therapy in subjects with HR+, HER2- locally advanced and unresectable…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Emory University, Atlanta, Georgia
    Locations
    8 in total
    Run by
    Regor Pharmaceuticals Inc.

    See if you can join NCT05304962 on ClinicalTrials.gov

  12. Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

    The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal g…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Winship Cancer Institute at Emory University, Atlanta, Georgia
    Locations
    3 in total
    Run by
    Reshma L. Mahtani, D.O.

    See if you can join NCT06263543 on ClinicalTrials.gov

  13. E-Mindfulness Approaches for Living After Breast Cancer

    NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wi…

    Stage
    Phase 3
    Ages
    18 to 50
    Site
    Grady Health System, Atlanta, Georgia
    Locations
    383 in total
    Run by
    NRG Oncology

    See if you can join NCT06748222 on ClinicalTrials.gov

  14. Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

    The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with breast cancer who require radiotherapy to the breast/chest wal…

    Stage
    Phase 3
    Ages
    19 and older
    Site
    Emory Proton Therapy Center, Atlanta, Georgia
    Locations
    9 in total
    Run by
    Proton Collaborative Group

    See if you can join NCT05856773 on ClinicalTrials.gov

  15. First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherap…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Winship Cancer Institute, Emory University, Atlanta, Georgia
    Locations
    65 in total
    Run by
    Eli Lilly and Company

    See if you can join NCT05768139 on ClinicalTrials.gov

  16. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

    A Study of Emi-Le in Participants with Solid Tumors

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Winship Cancer Institute, Emory University, Atlanta, Georgia
    Locations
    26 in total
    Run by
    Day One Biopharmaceuticals, Inc.

    See if you can join NCT05377996 on ClinicalTrials.gov

  17. Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

    This clinical trial adapts and evaluates the effectiveness of a family history screening program (GA CORE) for increasing uptake of genetic screening for BRCA-associated cancers in women who have received care in rural public health clinics in Southwest Georgia. Brief and low-cost family history-ba…

    Stage
    Not phased
    Ages
    25 and older
    Site
    Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
    Run by
    Emory University

    See if you can join NCT06760507 on ClinicalTrials.gov

  18. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Winship Cancer Institute of Emory University, Atlanta, Georgia
    Locations
    42 in total
    Run by
    QuantumLeap Healthcare Collaborative

    See if you can join NCT01042379 on ClinicalTrials.gov

  19. Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

    This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Emory University Winship Cancer Institute, Atlanta, Georgia
    Locations
    7 in total
    Run by
    Massachusetts General Hospital

    See if you can join NCT03990896 on ClinicalTrials.gov

  20. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Emory University Hospital Midtown, Atlanta, Georgia
    Locations
    202 in total
    Run by
    Pfizer

    See if you can join NCT07062965 on ClinicalTrials.gov

  21. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Emory Winship Cancer Institute, Atlanta, Georgia
    Locations
    18 in total
    Run by
    Incyclix Bio

    See if you can join NCT05735080 on ClinicalTrials.gov

  22. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage
    Not phased
    Ages
    Any age
    Site
    Massive Bio SYNERGY-AI site, Atlanta, Georgia
    Locations
    68 in total
    Run by
    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov

  23. MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles

    The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enabl…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Piedmont Cancer Institute, Atlanta, Georgia
    Locations
    134 in total
    Run by
    Agendia

    See if you can join NCT03053193 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.